金河生物 (002688.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

20.2x

Market Cap

CNY 3.99B

MomentumView details →

1D Return

+0.19%

YTD Return

−11.26%

RSI (14)

53.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

20.2x

Market Cap

CNY 3.99B

RSI (14)

53.3

MomentumView details →

1D Return

+0.19%

YTD Return

−11.26%

ProfitabilityView details →

Gross Margin

33.90%

Net Margin

1.29%

EBITDA Margin

9.30%

ROE (TTM)

1.70%

ROA (TTM)

0.67%

Asset Turnover

0.53x

GrowthView details →

Revenue YoY

+20.94%

EPS YoY

−61.87%

FCF YoY

−29.11%

Revenue CAGR 3Y

+10.68%

EPS CAGR 3Y

−28.58%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.79x

Current Ratio

1.30x

Quick Ratio

0.90x

Div Yield

1.89%

Div Rate

CNY 0.10

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

2.99B

Net Income (TTM)

38.74M

Op. CF (TTM)

429.73M

Latest newsMore news →

Jinhe Biotechnology announced its first-half 2026 results: revenue of 1.448 billion yuan, up 4.13% year-on-year; net profit attributable to shareholders of 131 million yuan, down 5.09% year-on-year.8d ago

Similar companies

天邑股份300504.SZ 华茂股份000850.SZ 华帝股份002035.SZ 立方制药003020.SZ 博晖创新300318.SZ 福恩股份001312.SZ Find similar companies →

Latest newsMore news →

Jinhe Biotechnology announced its first-half 2026 results: revenue of 1.448 billion yuan, up 4.13% year-on-year; net profit attributable to shareholders of 131 million yuan, down 5.09% year-on-year.8d ago